ZURA — Zura Bio Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1855644 ·
Last close
$4.21
Market Cap
$399.45M
52W High
$7.44
52W Low
$3.96
ADV30
677,320
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -25,499,000 | -24,223,000 | 228,641,000 | 225,594,000 | 11,745,000 |
| Dec 2025 | 0 | — | -18,411,000 | -17,175,000 | 113,948,000 | 109,407,000 | 12,410,000 |
| Sep 2025 | 0 | — | -19,519,000 | -18,040,000 | 143,935,000 | 139,017,000 | 25,491,000 |
| Jun 2025 | 0 | — | -18,062,000 | -15,993,000 | 157,805,000 | 154,490,000 | 18,696,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,815,000
Investing CF
$-113,000
Financing CF
$-2,163,000
CapEx
$-113,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-224,547,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-75,246,000
Pretax Income TTM
$-68,650,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -75,246,000 | -68,650,000 | 113,948,000 | 12,410,000 | — | -64,815,000 |
| Dec 2024 | 0 | -55,189,000 | -52,403,000 | 179,533,000 | 19,514,000 | — | -28,076,000 |
| Dec 2023 | 0 | -62,638,000 | -60,360,000 | 100,843,000 | 21,292,000 | — | -15,054,000 |
| Dec 2022 | 0 | -27,162,000 | -25,738,000 | 5,262,000 | 27,318,000 | — | -1,202,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | $396.19M | $2.20 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
| IPSC | Century Therapeutics, Inc. | $391.37M | $2.17 | — |
| CCCC | C4 Therapeutics, Inc. | $385.88M | $3.49 | — |
| REPL | Replimune Group, Inc. | $379.83M | $4.60 | — |
News headlines (Yahoo Finance, 1h cache)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 11:30 · Yahoo
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
2026-05-13 11:30 · Yahoo
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 11:30 · Yahoo
One Zura Bio Insider Raised Their Stake In The Previous Year
2026-04-23 10:06 · Yahoo
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
2026-03-19 20:05 · Yahoo
UniFirst, Elastic NV, and More Stocks See Action From Activist Investors
2026-03-07 02:31 · Yahoo
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
2026-03-05 11:30 · Yahoo
Zura Bio to Participate in Upcoming Investor Conferences
2026-03-02 11:30 · Yahoo
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-02-27 11:30 · Yahoo
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
2026-02-25 20:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.